Welcome to our dedicated page for China Pharma Holdings news (Ticker: CPHI), a resource for investors and traders seeking the latest updates and insights on China Pharma Holdings stock.
China Pharma Holdings, Inc. (NYSE American: CPHI) is a pharmaceutical company headquartered in Haikou, China. The company specializes in the development, manufacturing, and marketing of pharmaceutical products targeted at high-incidence and high-mortality diseases prevalent in the People's Republic of China. Its core business revolves around producing a variety of dosage forms including dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.
China Pharma’s diverse product portfolio consists of well-known drugs such as cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, and ozagrel sodium for injection, among others. A recent notable achievement is the receipt of the 'Drug Supplementary Application Approval Notice' from the National Medical Products Administration (NMPA) of China for its candesartan tablets, signifying their quality and efficacy consistency with generic drugs.
The company has also taken significant steps in the medical device sector. For instance, its Dry Eye Disease (DED) therapeutic device recently passed third-party testing and is preparing for market launch approval. This highlights China Pharma’s commitment to diversifying its offerings and addressing a broad spectrum of medical needs in China.
Financially, China Pharma operates a cost-effective business model driven by market demand and supported by new GMP-certified product lines. The company’s extensive and expanding nationwide distribution network ensures a robust presence across all major cities and provinces in China. The company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., plays a pivotal role in its manufacturing capabilities.
China Pharma continues to expand its market presence and competitive edge by participating in China’s national centralized procurement, enhancing its potential for growth in government procurement sectors. The company remains focused on improving public health outcomes through affordable and effective medication, while also aiming to generate significant value for its shareholders.
For more information, please visit www.chinapharmaholdings.com.
China Pharma Holdings, Inc. (NYSE American: CPHI) has announced plans to launch its Dry Eye Disease Therapeutic Device in China by Q1 2025. The device, developed by its subsidiary Hainan Helpson Medical and Biotechnology Co., , is a patented medical treatment for dry eye disease. With 400 million dry eye disease patients in China, the market is projected to reach $579.51 million by 2030, growing at a CAGR of 6.04% from 2023-2030.
The device uses ophthalmic oxygen-enriched atomization technology to spray tiny oxygen-rich droplets into the eyes, improving moisture, oxygen supply, and tear fluid quality. This physical therapy approach aims to avoid drug-related side effects while providing more direct and comfortable treatment.
China Pharma Holdings Inc. (NYSE American: CPHI) announced a 1-for-10 reverse stock split effective March 6, 2023. This decision was approved unanimously by the Board of Directors and stockholders at the Annual Meeting held on December 27, 2022. Following the split, the new CUSIP number for common stock will be 16941T-203. Each stockholder's percentage interest will remain unchanged, although fractional shares will be rounded up to the nearest whole share. China Pharma specializes in pharmaceuticals targeting high-incidence diseases in China, and maintains a broad distribution network across the country.
China Pharma Holdings, Inc. (NYSE American: CPHI) announced the launch of the N95 medical protective mask on December 26, 2022, following the issuance of a Registration Certificate by the Hainan Medical Products Administration. As COVID-19 cases surge in China, the demand for high-level medical protective masks has skyrocketed, leading to significant shortages in availability. CEO Li Zhilin highlighted the company's swift response to expand product lines for public health. This strategic move aims to optimize production capacities and ensure a stable supply of essential medical materials amidst the ongoing pandemic.
China Pharma Holdings, Inc. (NYSE American: CPHI) announced its drugs were listed in The Catalogue of Medicines for People Infected with COVID-19 on December 12, 2022. This follows China's end of strict COVID-19 policies, increasing public demand for related medications. Key products listed include the anti-viral Andrographolide and cold medicine Pusen OK. Additionally, recent regulatory changes will boost sales of roxithromycin and cefaclor. The company anticipates rising demand for health-related products amid the ongoing epidemic.
China Pharma Holdings, Inc. (NYSE American: CPHI) has announced the acquisition of a patented therapeutic device targeting Dry Eye Disease (DED). With DED affecting 25-30% of the population in China, and 75% of those over 65, the company aims to fill a significant market gap. The DED drug market in China was valued at about RMB3.85 billion in 2021, growing at 12.4%. The company has established sales channels in over 30 hospitals, enhancing its ability to promote the new device. CEO Li Zhilin highlighted the growing need for effective DED treatments due to increased screen time and an aging population.
On December 1, 2022, China Pharma Holdings, Inc. (NYSE American: CPHI) received a notification from NYSE American regarding noncompliance with listing standards due to insufficient stockholders' equity, reported at $2.8 million as of September 30, 2022. This falls below the $4.0 million minimum required after reporting net losses for four consecutive fiscal years. If compliance is not achieved by December 15, 2023, delisting proceedings may commence. The Company remains operational and its stock will continue to trade while it seeks compliance.
On September 26, 2022, China Pharma Holdings, Inc. (NYSE American: CPHI) received a Deficiency Letter from NYSE American for failing to meet listing standards. The letter indicated that the company's stock has traded below $0.20 on average for the past 30 days, as of September 22, 2022. The company must either conduct a reverse stock split or demonstrate sustained price improvement by March 26, 2023. The notification does not impact the company’s operations or obligations under SEC regulations. CPHI aims to regain compliance with the listing standards.
FAQ
What is the current stock price of China Pharma Holdings (CPHI)?
What is the market cap of China Pharma Holdings (CPHI)?
What does China Pharma Holdings, Inc. do?
Where is China Pharma Holdings, Inc. based?
What are some of the products offered by China Pharma?
What recent achievement has China Pharma made?
What is the significance of the NMPA approval for China Pharma?
What is China Pharma's business model?
How extensive is China Pharma's distribution network?
What new product is China Pharma planning to launch?
When will the reverse stock split for China Pharma be effective?
How can I find more information about China Pharma Holdings, Inc.?
